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Objective: To correlate the incidence of hemorrhage and thrombosis to bleeding time (BT) and platelet aggregation in 27 consecutive
patients with myeloproliferative diseases (MPD). Design: Retrospective study. Setting: Public tertiary referral center.
Patients: Eighteen patients with chronic myelogenous leukemia (CML), 5 with polycytemia vera (PV), 2 with essential thrombocytemia
(ET) and 2 with idiopathic myelofibrosis (MF). Duke's BT and epinephrine-induced platelet aggregation were performed on the patients
and on 10 healthy individuais. Results: Eleven patients presented symptoms (41 %): 9 with hemorrhage (33%) and 5 with thrombosis
(19%). There were less symptomatic patients in the CML group (28%) than in the other MPD (67%), without statistical significance
(Fisher, p=0.06). Duke's BT was longe r in symptomatic patients (Mann-Whitney, p<0.05). Platelet aggregation was abnormal in 7 patients
(26%) and 71 % of them were symptomatic (Fisher, p = 0.07).
Conclusions: The high incidence of bleeding and thrombosis in patients. with MPD was related to prolonged BT, but not to platelet
aggregation abnormalities.
UNITERMS: Myeloproliferative Diseases. Hemorrhage.Thrombosis. Bleeding time. Platelet aggregation.
INTRODUCTION
Both hemorrhagic aod thrombotic episodes accountfor the morbidity and mortality inmyeloproliferative diseases (MPD)'. Either
phenomena may be related to acquired platelet
abnormalities observed in some patients, such as increased
platelet production or destruction, altered platelet secretory
granular content, changes in glycoprotein concentrations
and abnormal response to aggregating agents, especially
epinephrine. The incidence of all these platelet abnormalities
in patients with MPD has been published in a
cc:>mprehensive review of 124 studies by Holme et a1.2•
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The aim of this study was to verify the incidence of
thrombotic or hemorrhagic complications in patients with
MPD, followed up for a 2 year period, and to correlate
them to the bleeding time and platelet aggregation induced
byepinephrine.
MATERIAL AND METHODS
Patients
The authors evaluated 27 consecutive patients with
MPD attending the Hematology Department ofUNIFESP.
There were 18 patients with chronic myelogenous leukemia
(CML), 5 with polycytemia vera (PV), 2 with essential
thrombocytemia (ET), and 2 with idiopathic myelofibrosis
(MF). Diagnosis was established according to standard
crÍteria considering blood cell count, peripheral blood smear
analysis, bone marrow aspiration and biopsy, blood and
plasma volume studies, leukocyte alkaline phosphatase
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(MPD= myeloproliferative diseases, CML= chronic myelogenous
leukemia, PV= polycythemia vera, ET = essential thrombocythemia,
MF= myelofibrosis).
labia 1
Patient distribution according to the
myeloproliferative disease, and the presence of
hemorrhage or thrombosis
N% Hemorrhage Thrombosis 80th Total
N N N N%
CML 13 (72%) 3 O 2 5 (28%)
PV 1 (20%) 2 1 1 4 (80%)
ET 1 (50%) 1 O O 1 (50%)
MF 1 (50%) O 1 O 1 (50%)
TOTAL 16 (59%) 6 (22%) 2 (8%) 3 (11 % ) 11 (4 1% )
and the occurrence of hemorrhage or thrombosis is shown
in Table 1. The CML group presented a lower incidence of
symptomatic patients (28%), compared to the other MPD
(67%) [ PV (80%); MF (50%); ET (50%) ], but this
difference did not reach statistical significance (Fisher test,
p=0.06). Hemorrhage was presented as spontaneous
ecchymoses in 3 patients, gingival bleeding in 2, epistaxis
in 4, gastrointestinal bleeding in 2, and retinal hemorrhage
in 1. Thrombotic episodes included: deep vein thrombosis
in 2 patients, transitory ischemic attack in 1, ischemic
cerebral attack in 1, and acute arterial occlusion in the
absence of arterial disease in 1.
Mean Duke's BT was 1.8 minutes (min) in patients
and 1.3 min in controls and this difference was not
statistically significant (Mann- Whitney test, p>0.05).
Symptomatic patients had longer Duke's BT (mean .:t
SD=2.2.:t 1.0min) than asymptomatic (mean.:t SD=1.6.:t
0.81min) and controls (mean.:t SD=1.3.:t 0.53min), but a
statistically significant difference was seen only between
symptomatic patient~ and controls (Mann- Whitney test,
p<0.05) (Figure 1).
Platelet aggregation pattem was abnormal in 7 patients
(26%): 5 out of 18 with CML (28%), 1 out of 2 with ET
(50%), and 1 out of2 with MF(50%). AlI patients with PV
had normal platelet aggregation (Table 2). No difference
was seen between the frequency of abnormal platelet
aggregation in the CML group, compared to the other MPD
(Fisher test, p=0.57).
Symptomatic patients had a higher incidence of
abnormal platelet aggregation patterns (46%) than
Symptomatic PatientsMPD Asymptomatic
Patients
score and cytogenetic study3. Patients' ages ranged from
16 to 75 years (average = 56 years), and there were 11men
and 16 women. All ofthem were evaluated as outpatients.
Patients were being treated with either hydroxyurea or
bussulfan as chemotherapy. Only one patient, who had a
transitory ischemic attack, was taking aspirin, which was
discontinued 10 days before blood sampling. Ten healthy
individuaIs, 7 women and 3 men, from the Iaboratory staff
constituted the controI group. Their age ranged from 27 to
69 years (average = 38 years).
Eleven out of the 27 patients (41 %) had
thrombohemorrhagic manifestations: 6 presented
hemorrhage, 2 presented thrombosis and 3 presented both
features. Patient distribution according to the type ofMPD
RESULTS
Methods
Blood cell counts were performed automatically in a
Coulter counter and platelet counts were made in Neubauer
chambers, with phase microscopy.
Bleeding time was performed according to Duke's
technique, and consisted of a small incision in the earlobe
using a sterile lanceto The cut was blotted every 30 seconds
with filter paper until bleeding stopped. Results were
recorded in minutes4•
Platelet aggregation study was performed on platelet
rich plasma (PRP) obtained from citrated whole blood, using
a Minigator II-Payton Scientific Aggregometer, according
to Bohr5. Platelet count on PRP was adjusted to 300 x 109/L.
Epinephrine was used as an aggregating agent at a final
concentration of2.2 mM. Normal individuaIs presented two
aggregation waves and this was considered to be the normal
pattern. Patients were classified as having an abnonnal
aggregation pattern when there was either a single wave or
a complete absence of aggregation. All patients were
evaluated on two occasions, at least one month apart, and
were considered abnormal only when they presented the
abnormal pattern in both analysis. To evaluate the assay
conditions, blood from healthy volunteers was collected
daily as a controI.
The frequency of symptomatic and asymptomatic
patients, as well as the frequencies of normal and abnormal
platelet aggregation patterns, were compared using the
Fisher exact testo The Mann- Whitney test was used to
compare bleeding time in patients and controls.
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asymptomatic ones (13%), but this difference did not reach
statistical significance (Fischer test, p=0.07).
There was no significant difference between Duke's
BT in patients with abnormal platelet aggregation (mean:t
SD=2.0:t 1.0min) and those with normal patterns (mean:t
SD=I.8:t 0.95 min) (Mann-Whitney test, p>0.05).
DISCUSSION
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Figure 1 - Ouke's bleeding time in patients and controls.
The frequency ofthrombohemorrhagic complications
in MPD varies in different studies, and some reported data
are presented in table 3. The authors observed a higher
incidence ofhemorrhage (33%) than thrombosis (19%), in
27 patients with MPD. Similar findings have been reported
by Adams et aI.6, Walsh et aI. 16,and Bush et
aI.7, who studied 21, 16 and 72 patients with
Table 2 MPD, respectively. However, Barbui et aI.I2
Results of platelet counts, bleeding time and platelet aggregation in a large series of 101 patients observed that
according to myeloproliferative disease
---------------------------- the incidence ofhemorrhage and thrombosis
Platelet Aggregation were similar, whereas Zucker et aI. found that
thrombosis was more common 11.
The relatively lower incidence of
hemorrhage in patients with CML, compared
to other MPD, was also observed by other
authors7, 15.As pointed out by Schaferl,
cutaneous and mucous membrane were the
most common sites of bleeding.
Duke's BT was longer in symptomatic
patients, compared to asymptomatic ones and
controls. In fact, the occurrence of prolonged
bleeding time was reported by some authors,
but in no case was there a positive correlation
between BT and the presence of
hemorrhagel3, 15,16. BT is an "in vivo"
measuring of primary hemostasis, that
depends not onl y on platelet function, but also
on complex interactions among platelets,
subendothelium, and von Willebrand factorl7•
The prolonged BT in patients who presented
hemostatic complications suggests that these
individuaIs may have an altered platelet/
endothelium interaction that could favor the
occurrence of thrombosis or hemorrhage.
A prolonged Duke's BT correlates with
hemostatic defects that are clinicall y relevant,
probably better than does the Ivy BT, which
(NO= not done, MPO= myeloproliferative diseases, CML= chronic myelogenous may be prolonged even in asymptomatic
leukemia, PV= polycythemia vera, ET= essential thrombocythemia, MF= patients 18.myelofibrosis)
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Table 3
Frequency of hemorrhage, thrombosis and abnormal platelet aggregation in patients with MPD
(NS=not stated)
Author N Hemorrhage Thrombosis Altered Platelet
(%) (%) Aggregation (%)
Zucker. (11), 1972 12 25 33 32
Adams ( 6), 1974 21 29 O 76
Ginsburg ( 9), 1975 19 16 26 62
Walsh (8), 1977 1.6 19 12,5 75
Waddell (10), 1981 18 11 17 NS
Barbui (12), 1983 101 11 10 39
Buss (7), 1985 72 36 14 NS
Raman (13), 1989 43 16 16 56
Present study, 1994 27 33 19 26
The frequency of abnormal platelet aggregation
induced by epinephrine ranged from 32% to 76% in the
reported series (Table 3). This great variability could be
due to the epinephrine concentrations used in the different
assays. In the present study, abnormal platelet
aggregation was observed in only 26% ofthe 27 patients,
maybe because the patients were considered abnormal
only when they present the alteration on two different
occasions.
Some authors reported altered platelet aggregation
induced by other agents, such as ADP and collagen,
although the incidence of low responsiveness to
epinephrine has been the most common finding in these
studies 13.20.
71% of patients with abnormal and 30% with normal
platelet aggregation were symptomatic, but no statistical
difference was seen. Therefore platelet aggregation pattern
seems not to predict the occurrence of bleeding in patients
with MPD, as observed by othersI0.15.19.
In conclusion, the authors observed a high incidence
(41 %) of bleeding or thrombotic events in 27 patients with
MPD. Duke's BT could discriminate the symptomatic
patients, while platelet aggregation induced by epinephrine
proved to be useless for this purpose.
Objetivos: Relacionar a incid~ncia de sintomas tr()mbo~hemo~rágicoscom tempo de (TS) e agregaçãO plaquetária.__
em pacientes com doenças mieloproliferativas crqnicas(DMP). Desenho: Estudo Local: Hospital público terciário
- UNIFESP-EPM. Participantes: Vinte e sete pacientes ambulatoriais, consecutivos, DMR EstudadoTS de Duke e agregação
plaquetária induzida pela adrenalina~ comparando a>1° indivíduos saudáveis. Mensuração: Arlálise estatística., com nível de
significância menor ou iglJaLà 5°/o,(p<= O.05)~Re~LJltados:Onze pacientes sintomátiços (41%) : 9com hem()rragia (33%) e 5
com trombose (19%). Os pacientes com leucemia mielóide crônica apresentaram menos sintomas (28%) que os portadores de
outras DMP (67%), sem significância estatística (Fisher, p=O,06). O TS de Duke foi maior em pacientes sintomáticos (Mann.;.
Whitney, p<O,05).Agregação plaquetária anormal em 7 pacientes (26%), sendo 71% sintomáticos (Fisher, p=O.07). Conclusões:
A incidência de hemorragia ou trombose nos pacientes com DMP foi relacionada com T~ prolongado mas não com alterações na
agregação plaquetária.
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